Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic test may flag type 1 diabetes risk years before symptoms

NCT ID NCT07802496

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

Researchers at Mass General Brigham are testing whether genetic information can help identify people who might benefit from early screening for type 1 diabetes, even before they feel sick. The study involves 150 adults from the MGB Biobank who agreed to be recontacted. Participants will have their genetic risk for type 1 diabetes assessed, and those at high risk will also be tested for diabetes-related autoantibodies. The goal is to see if this approach can improve screening and guide future prevention efforts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Genetic screening and autoantibody testing
What this could lead to
If it works, this could point toward earlier detection and prevention of type 1 diabetes, even before symptoms appear.
What could go wrong
This is an early, exploratory study with only 150 participants. The genetic test may not reliably predict who will develop the disease, and the results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18-79 years who had participated in the Mass General Brigham (MGB) Biobank and agreed to be recontacted for future study

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-79 years who had participated in the Mass General Brigham (MGB) Biobank and agreed to be recontacted for future study Exclusion Criteria: * Individuals with current or prior treatment with immune checkpoint inhibitors (e.g., PD-1, PD-L1, or CTLA-4 inhibitors), as well as individuals with diabetes secondary to pancreatic disease, including pancreatic cancer, pancreatitis, pancreatic surgery/pancreatectomy, cystic fibrosis, or hemochromatosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.